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Cover title: Can we improve the statistical analysis of stroke trials? Most large acute stroke trials have been neutral. Functional outcome is usually analysed using a yes or no answer, e.g. death or dependency vs. independence. We assessed which statistical approaches are most efficient in analysing outcomes from stroke trials.
Methods
Individual patient data from acute, rehabilitation and stroke unit trials studying the effects of interventions which alter functional outcome were assessed. Outcomes included modified Rankin Scale, Barthel Index, and '3 questions'. Data were analysed using a variety of approaches which compare two treatment groups. The results for each statistical test for each trial were then compared.
Results
Data from 55 datasets were obtained (47 trials, 54,173 patients). The test results differed substantially so that approaches which use the ordered nature of functional outcome data (ordinal logistic regression, t-test, robust ranks test, bootstrapping the difference in mean rank) were more efficient statistically than those which collapse the data into 2 groups (chi square) (ANOVA p<0.001). The findings were consistent across different types and sizes of trial and for the different measures of functional outcome.
BACKGROUND
The management of patients with acute or recent stroke has benefited significantly from the results of randomised controlled trials and meta-analyses of these. For example, functional outcome is improved with alteplase, aspirin, management in a Stroke Unit, and community occupational therapy. [1] [2] [3] [4] [5] [6] [7] In contrast, some studies were overtly negative finding that treatment worsened outcome, e.g. DCLHb, enlimomab, selfotel, or tirilazad. [8] [9] [10] [11] However, the majority of acute stroke trials were neutral in spite of positive preclinical findings. The failure of these latter studies can be attributed to multiple causes, including the relevance of laboratory findings to clinical stroke, 12 inadequate sample size, 13 choice of primary outcome, and its statistical analysis.
Measures of functional outcome such as the modified Rankin Scale (mRS) 14 , Barthel Index (BI) 15 and '3-questions'' 16 are ordinal in nature, that is, they consist of 3 or more categories which have a natural ordering, e.g. the mRS has 7 categories ranging from no symptoms to dead. It might then be expected that statistical analysis would preserve and utilise the data in this ordinal form. However, most published trials have used a 'yes/no' (dichotomised) analysis of functional outcome, e.g. combining categories within the mRS into two groups, such as 'dead or dependent' (e.g. mRS 3-6) and 'independent' (mRS 0-2), and then comparing these between the treatment groups. Unfortunately, there is little agreement where mRS data should be divided:
i.e. 0,1 vs. 2-6, 1 0-2 vs. 3-6, 17 or 0-3 vs. [4] [5] [6] 18 and whether this matters. 19 Further, collapsing data in this way generally lowers statistical power and therefore reduces the chance of finding a significant treatment effect since information from many subjects are ignored. For example, patients responding to treatment and achieving a 4 mRS of 3 rather than 4 or 0 rather than 1 are not detected in a analysis comparing mRS 0-2 with 3-6.
Inadequacies in the statistical analysis of trials in acute stroke are apparent in two examples. First, the ECASS II trial of alteplase showed no treatment effect for its primary outcome (when comparing mRS 0,1 with mRS 2-6) but was positive when reanalysed using the data collapsed in a different place (mRS 0-2 vs. 3-6) 20 or when analysed using a 'bootstrapping' technique (figure 1). 21 Second, five trials of tirilazad individually showed no treatment effect when analysed using dichotomous outcomes 22-24 although a meta-analysis found that the intervention was associated with a worse outcome; 25 post hoc analysis then suggested that one of these trials was negative 24 (not neutral) when analysed using a method which preserved the original ordered data (P Bath, unpublished data).
We aimed to identify which statistical methods might optimise the analysis of data from functional outcome scales in stroke trials.
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METHODS
Identification of trials
We sought individual patient data from randomised controlled trials assessing functional outcome after stroke for interventions which were either positive or negative according to the trial publication, or were included in a meta analysis showing benefit or harm; neutral trials in a neutral meta-analysis were excluded.
Published studies (full paper or abstract) fulfilling these criteria were identified from electronic searches of the Cochrane Library (to end of 2005). In each case, we invited the chief investigator to join the collaboration and share their data. In some cases where individual data could not be obtained it was possible to extract it from the original publication.
Trial data
Demographic (age, gender), trial (setting, intervention, length of follow up, result), patient severity, and functional outcome (BI, mRS, '3 question' scale [3Q, a derivative of mRS], or another measure) data were collected for each trial. In factorial trials or those having more than two treatment groups, data were analysed for each comparison of active therapy versus control. Where outcome data were scored at several time points (e.g. 1, 3 and 6 months) the time point used for the primary outcome was included.
Statistical tests
We compared different statistical tests for assessing treatment effect. Some of these required the data to be collapsed into groups (such as the chi square test) while others used the original ordinal data (such as Wilcoxon test and t-test). Statistical tests which dichotomised ('yes/no') data were assessed multiple times collapsing the 6 data in different places, e.g. mRS 0,1 vs. 2-6, 0-2 vs. 3-6 and 0-5 vs. 6. A description of the statistical tests used is given in http://www.nottingham.ac.uk/strokemedicine/oast/oastappendix1.doc.
Comparison of statistical tests
Each data set was analysed using each statistical test. These results were then ordered within each trial and given a rank, with the lowest rank given to the test which produced the most significant result, i.e. the largest z score, within that trial. A two-way analysis of variance test was then used to see on average which statistical test had produced the lowest ranks. We were then able to order the statistical tests in terms of their efficiency in identifying treatment effects. We also assessed how many statistically significant (at 5%) results each test found.
To assess the validity and reliability of the results, a number of supplementary analyses were carried out. First, the comparison of statistical tests was repeated within sub-groups of trials sharing similar characteristics; second, the statistical assumptions of the tests were assessed; and last, the sensitivity of the tests was explored to make sure treatment effects were only detected when they truly existed (the type one error rate). Technical details of these supplementary analyses can be found in http://www.nottingham.ac.uk/stroke-medicine/oast/oastappendix2.doc.
Analyses were carried out in SAS (version 8.2) and Stata (version 7) and significance was taken at p<0.05.
RESULTS
Trials characteristics
A total of 55 comparisons of active versus control treatment (54,173 patients) were included, these comprising individual patient data from 38 trials and summary data extracted from the publications of a further 9 studies; six trials had two active treatment groups, and one had three active groups so a further 8 comparisons were available (figure 2 which compared means; the remaining trials were unpublished so the method of analysis is not known.
Comparison of statistical tests
The statistical tests assessed differed significantly in the results they gave for each trial (2 way ANOVA p<0.0001). The ordering of the tests showed that those which analyse the original ordinal data generally perform better than those which collapse the data into 2 or more groups. The most efficient tests included ordinal logistic regression, t-test, robust rank test and bootstrapping the difference in mean rank (table 1 When assessed by how many trials were statistically significant, those tests which did not collapse the data into groups again out-performed the other approaches; for example, ordinal logistic regression (using raw data) gave a statistically significant result in 25.9% of trials whereas the 2x2 chi-square test comparing death or poor outcome to an excellent outcome only gave a significant result in 9.3% of the trials (figure 3).
Test assumptions and sensitivity
The statistical assumptions of the t-test were not met for the majority of trials and the assumptions of the ordinal logistic regression analysis failed for 8 out of the 55 data sets; in contrast, the assumptions for the other tests were maintained. The sensitivity analysis showed that the top performing statistical tests were not overly sensitive and
DISCUSSION
These results show that statistical approaches which analyse the original ordinal data for functional outcome are more efficient than those which work on pre-processed data which has been collapsed into 2 or more groups. Interestingly, this point was originally demonstrated mathematically by Shannon in 1948 27 . In particular, ordinal logistic regression, t-test, robust ranks test, and bootstrapping (the difference in mean rank) performed well and appear to be useful irrespective of the type of stroke trial, patient or intervention. Although individual tests based on dichotomised data using Chi-square analysis (e.g. 'dead/dependent' versus 'independent') were effective for some data sets, they performed poorly in many and therefore cannot be recommended as general solutions for analysing stroke trials. From an historical perspective, it is quite possible that trials which collapsed mRS or BI in two groups may have used a sub-optimal analysis, and this may have contributed to false neutral findings in some cases in the past. For example, MAST-E 28 and STIPAS 24 were neutral as reported using dichotomous analysis but negative when assessed with ordinal approaches.
Several comments can be made about this study. First, it aimed to include data from all stroke trials assessing a beneficial or harmful intervention. Unfortunately, data
were not made available for all identified trials; where possible, we created individual data from publications which provided patient numbers by outcome score. Data were missing for a variety of trial types (acute/rehabilitation/stroke unit) and sizes, and functional outcome measure (mRS/BI), so it is unlikely that a systematic bias was introduced into the findings; however, the precision of the results may have been attenuated by the missing trials. Second, we did not exhaustively search for all possible statistical tests relevant to the problem of analysing ordered categorical data; instead, we focussed on those approaches which are available in standard statistical textbooks and computer packages. Additionally, we could not include some tests used in recent trials, e.g. patient specific outcomes 29 and Cochran Mantel Haenszel test 30 since these require access to individual data for both baseline and outcome variables, and these data were not available uniformly. Third, some of the statistical assumptions underlying the more efficient tests were not met in all trials; for example, the t test assumes data are normally distributed while ordinal logistic regression assumes that any treatment effect is similar across outcome levels ('proportionality of odds', i.e. the odds of moving a treated patient from mRS 2 to 1 is similar to that for moving them from 5 to 4). Nevertheless, the robustness of these tests to deviations from their underlying assumptions means that they remain relevant for analysing functional outcome data from stroke trials.
If alternative approaches to analysing functional outcome data are to be used in the future, it is pertinent to ask how sample size should be calculated at the trial design stage. Historically, most calculations assumed that functional outcome would be dichotomised and analysed using a Chi-square test approach. 13 Although future trials could continue to calculate sample size in the same way (and then gain extra power by analysing their data using an ordinal approach), specific sample size calculations are available when data are to be analysed using ordinal logistic regression 31 or the ttest. Ideally, the extra power gained by using an ordinal statistical approach should not be used to reduce sample size; stroke trials have been too small in the past, as shown in a recent meta analysis, 13 and this may also have contributed to the failure of some of them.
A further issue with using a statistical test which analyses ordered categorical data is how to report the results to patients, carers, clinicians, and health policy makers. The results of dichotomous tests may be summarised easily as the proportion of patients who benefit (or suffer) with a treatment, i.e. alteplase reduced absolute death or dependency (mRS>1) by 13% in the NINDS part 2 trial. 1 In contrast, ordinal tests will need to be presented as the average absolute improvement in outcome, e.g. alteplase improved the mRS by 1 (of 7) point and BI by 22.5 (of 100) points. Alternatively, the combined odds ratio and its confidence intervals would be reported if ordinal logistic regression was used. In this respect, health consumers will need to decide what differences in mRS and BI are worthwhile, both clinically and in terms of health economics. In reality, it is reasonable to present the effect on functional outcome using both absolute percentage change and mean or median change in functional outcome score, and show this data graphically (as in figure 1 ).
In summary, we suggest that ongoing and future trials should consider using statistical approaches which utilise the original ordered categorical data in the primary analysis of functional outcome measures. Such ordinal tests include ordinal logistic regression, and the robust ranks test; the t-test may also be used although its assumptions were not meant in the majority of trials. Identification of included trials
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OAST bootstrap of difference in mean rank (with 3x3000 cycles [5, 6] ). Chisquare tests were performed without continuity correction since most trials enrolled more than 100 patients. Ordinal logistic regression provides one overall estimate for each covariate in the model and not one for each cut point. This assumes that the overall odds ratio is constant no matter which cut is taken. So, for example the odds ratio for the treatment effect would be interpreted as the odds of being in category j or above for all choices of j comparing treatment 1 to treatment 0. [7] Supplementary tables Table 1 Sixteen statistical tests compared and the data used for the three main scales compared. [1] [2] [3] Blank cells indicate that the data has not been collapsed into groups. Bootstrap difference in mean rank [5] OAST Appendix 2: Supplementary analyses
Excluded tests
Supplementary analyses
Sub group analysis Sub group analyses were performed by assessing the efficiency of the different tests for differing trial characteristics: type of intervention (acute drug treatment, rehabilitation, stroke unit); trial size (<500, >500 participants); time between randomisation and stroke onset (<6, >6 hours); patient age (median <70, >70 years); baseline severity (control group death rate adjusted for length of follow up, <median (0.05) ,>median); outcome measure (BI, mRS, 3Q); length of follow up (<3 months, >3 months); and trial result (positive, negative).
Statistical assumptions
The principal statistical assumptions underlying the tests which performed well were assessed to ensure that their use was appropriate for stroke trial data. Assumptions 
Type 1 error rate
It is conceivable that an overly sensitive statistical test might find significance in a trial when no real difference existed, a type 1 error. We assessed the type I error rate for the three most efficient statistical tests, using data from three representative trials including one of the three measures of functional outcome (BI: RANTTAS, [3] mRS:
NINDS,[4] 3Q: IST [5] ). From these we generated 1000 data sets, using random sampling with replacement, in which any treatment difference could have occurred only by chance. Tests maintaining adherence to the nominal type I error rate would expect to see a significant result in around 50 of the 1000 data sets. 11 [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Citicoline 7 [9] 14 [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] PROACT II [27] 12 [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] IQR: Inter quartile range; NIHSS: National Institute of Health Stroke Scale; hr: hours; w: weeks; mo: months; SU: stroke unit; OT: occupational therapy; PT: physiotherapy 
